Literature DB >> 12898575

Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.

Aiveen Kirley1, Naomi Lowe, Ziarih Hawi, Celine Mullins, Grainne Daly, Irwin Waldman, Mary McCarron, Deirdre O'Donnell, Michael Fitzgerald, Michael Gill.   

Abstract

Several studies have implicated the dopamine transporter gene (DAT1) as conferring susceptibility to attention deficit hyperactivity disorder (ADHD), in particular, a VNTR situated at the 3' end of the gene. In addition, the 10-repeat VNTR allele associated with ADHD has been reported to be associated with an over-active transporter protein (DAT). Thus children possessing this variant might be particularly responsive to methylphenidate, a drug known to act by blocking DAT. We have examined this hypothesis and now report an association between the 10-repeat VNTR DAT1 polymorphism and retrospectively rated methylphenidate response in a sample of 119 Irish children with ADHD (chi(2) = 7.918, df = 1, P = 0.005). Our findings suggest a role for the 10-repeat DAT1 risk allele in medication response and may help to predict positive clinical outcome in ADHD. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898575     DOI: 10.1002/ajmg.b.20071

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  38 in total

Review 1.  Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Authors:  Roberta Russo; Mario Capasso; Paolo Paolucci; Achille Iolascon
Journal:  Eur J Clin Pharmacol       Date:  2010-11-11       Impact factor: 2.953

Review 2.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

3.  Single-quantum-dot tracking reveals altered membrane dynamics of an attention-deficit/hyperactivity-disorder-derived dopamine transporter coding variant.

Authors:  Oleg Kovtun; Dhananjay Sakrikar; Ian D Tomlinson; Jerry C Chang; Xochitl Arzeta-Ferrer; Randy D Blakely; Sandra J Rosenthal
Journal:  ACS Chem Neurosci       Date:  2015-03-16       Impact factor: 4.418

4.  Dopamine transporter (DAT1) VNTR polymorphism in 12 Indian populations.

Authors:  L V K S Bhaskar; Kumarasamy Thangaraj; Connie J Mulligan; Samiksha Wasnik; Amrita Nandan; Varun Kumar Sharma; Vishwas Sharma; Alla Govardhana Reddy; Lalji Singh; Vadlamudi Raghavendra Rao
Journal:  Neurol Sci       Date:  2009-09-25       Impact factor: 3.307

Review 5.  Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics.

Authors:  Tanya E Froehlich; James J McGough; Mark A Stein
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 6.  Genetic aspects in attention-deficit/hyperactivity disorder.

Authors:  O Albayrak; S Friedel; B G Schimmelmann; A Hinney; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

Review 7.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

Review 8.  Pharmacology and pharmacogenetics of pediatric ADHD with associated aggression: a review.

Authors:  Bianca D Patel; Drew H Barzman
Journal:  Psychiatr Q       Date:  2013-12

Review 9.  The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy.

Authors:  Mark A Stein; James J McGough
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-04

10.  Gene expression profiles in the prefrontal cortex of SHR rats by cDNA microarrays.

Authors:  Jie Qiu; Qin Hong; Rong-hua Chen; Mei-ling Tong; Min Zhang; Li Fei; Xiao-qin Pan; Mei Guo; Xi-rong Guo; Xia Chi
Journal:  Mol Biol Rep       Date:  2009-07-02       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.